Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: findings from a multinational cohort between 2010 and 2019Daniela K van Santen, Margaret Hellard, Maria-Bernarda Requena et al.|EClinicalMedicine|2022Cited by 38
Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort CollaborationSophia M. Rein, Miguel A. Hernán, Sara Lodi et al.|The Lancet HIV|2023Cited by 32
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studiesRachel Sacks‐Davis, Coralie Khan, Daniela K van Santen et al.|The Lancet HIV|2024Cited by 24
Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)Daniela K van Santen, Ashleigh C. Stewart, Joseph Doyle et al.|International Journal of Epidemiology|2023Cited by 4
Time to direct-acting antiviral initiation and liver-related events in people with HIV and hepatitis C virusMathieu Chalouni, Sara Lodi, Daniela K van Santen et al.|AIDS|2025Cited by 2